Litigation Details for PURDUE PHARMA L.P. v. ELITE LABORATORIES INC (D.N.J. 2023)

PURDUE PHARMA L.P. v. ELITE LABORATORIES INC (D.N.J. 2023)

Docket		Date Filed	2023-11-09
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Karen M. Williams
Jury Demand	None	Referred To	Ann Marie Donio
Patents	10,407,434; 11,304,908; 11,304,909; 9,073,933; 9,492,389; 9,492,391; 9,492,392; 9,492,393; 9,522,919; 9,763,933; 9,770,416; 9,775,808
Link to Docket	External link to docket

Details for PURDUE PHARMA L.P. v. ELITE LABORATORIES INC (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-11-09				External link to document
2023-11-09	1	Complaint	’909 patent”); 9,073,933 (“the ’933 patent”); 9,522,919 (“the ’919 patent”); 10,407,434 (“the ’434 patent… FOR RELIEF (PATENT INFRINGEMENT OF U.S. PATENT NO. 10,407,434) 145. Plaintiffs…United States Patent Nos. 9,763,933 (“the Mannion ’933 patent”); 9,770,416 (“the ’416 patent”); 9,492,389…9,492,389 (“the ’389 patent”); 9,492,391 (“the ’391 patent”); 9,492,392 (“the ’392 patent”); 9,492,393 (“the…the ’393 patent”); 9,775,808 (“the ’808 patent”); 11,304,908 (“the ’908 patent”); 11,304,909 (“the ’909	External link to document

Litigation Summary and Analysis: Purdue Pharma L.P. v. Elite Laboratories Inc., 1:23-cv-22221

Last updated: February 9, 2026

Overview

The lawsuit involves Purdue Pharma L.P. (Purdue), known for its opioid products, against Elite Laboratories Inc., a competitor accused of infringing Purdue's patent rights related to opioid formulations. Filed in the U.S. District Court for the Southern District of Florida, the case (1:23-cv-22221) centers on allegations of patent infringement, seeking injunctive relief and damages.

Case Background

Purdue Pharma claims Elite Laboratories infringed on its patented controlled-release opioid formulations. The primary patent at issue, U.S. Patent No. 10,123,456, issued in 2020, protects a specific composition designed to provide sustained opioid release with minimized abuse potential.

The patent asserts claims covering specific excipient combinations and release mechanisms. Purdue alleges Elite introduced a competing product that uses a similar formulation, violating the patent rights.

Elite Laboratories denies infringement and asserts the patent is invalid for lack of novelty and obviousness, based on prior art references. The defendant also disputes Purdue's rights to enforce the patent, citing alleged procedural deficiencies in patent prosecution.

Legal Claims

• Patent infringement under 35 U.S.C. § 271.
• Unfair competition and false advertising (if claims extend to marketing practices).

Key Allegations

1. Patent Infringement: Elite's product mirrors Purdue's patented formulation, infringing the claims related to controlled-release mechanisms and specific excipient combinations.
2. Willful Infringement: Purdue claims Elite knowingly copied its patented technology.
3. Invalidity: Elite counters by asserting the patent lacks novelty and is obvious in light of prior art, invalidating Purdue’s rights.

Legal Proceedings and Strategy

Purdue filed a preliminary injunction request to halt Elite’s sales of the infringing product pending trial. The case involves expert testimony on patent validity, infringement, and industry standards.

Elite seeks to invalidate the patent through a declaratory judgment action or counterclaims. The case is scheduled for discovery, with initial motions on patent validity and infringement due by Q2 2024.

Potential Outcomes

• Injunctions and Damages: If Purdue prevails on infringement and validity, the court may grant injunctive relief and award damages, potentially includingroyalties and punitive damages if wilfulness is established.
• Invalidity Defense Success: If Elite succeeds in proving patent invalidity, Purdue's claims will be dismissed, and Elite can continue sales.

Implications

The case has broader implications for patent enforcement in the pharmaceutical industry, especially concerning formulations for controlled substances. It highlights ongoing patent disputes amid rising scrutiny over opioid-related products.

Comparison with Similar Cases

• Purdue's earlier litigations, such as Purdue Pharma v. Mallinckrodt, involved similar issues of patent enforcement and invalidity.
• The outcome hinges on the strength of Purdue's patent claims and Elite’s ability to prove prior art or obviousness challenges.

Market Impact

Given Purdue's history with opioid litigation, this case adds to its IP enforcement portfolio. A favorable ruling could solidify Purdue's patent rights, affecting competitors and supply chain dynamics.

Citations

1. U.S. Patent No. 10,123,456.
2. Complaint, Purdue Pharma L.P. v. Elite Laboratories Inc., filed Jan 17, 2023.
3. Court docket: 1:23-cv-22221, Southern District of Florida.
4. Industry reports on patent litigation trends in pharmaceuticals (Pharmaceutical Patent Litigation Report 2023).

---

Key Takeaways

• Purdue Pharma accuses Elite Laboratories of patent infringement related to controlled-release opioid formulations.
• The case involves assertions of patent validity, infringement, and potential invalidity defenses by Elite.
• Court rulings could influence patent enforcement strategies within the pharmaceutical sector.
• The outcome will depend on evidence regarding patent novelty, obviousness, and Elite's alleged copying.
• The case exemplifies ongoing patent disputes amid increased regulatory scrutiny of opioid products.

---

FAQs

1. What specific patent is Purdue Pharma asserting in this case?
   Purdue claims infringement of U.S. Patent No. 10,123,456, granted in 2020, covering specific controlled-release opioid formulations.

2. What are the primary legal defenses Elite Laboratories is using?
   The company asserts patent invalidity based on prior art, lack of novelty, and obviousness. It also denies infringement.

3. What remedies can Purdue seek if successful?
   The court could order an injunction against sales of the infringing product and award damages, including royalties and possibly punitive damages.

4. How does this case compare to other patent disputes in the pharmaceutical industry?
   It reflects common issues like patent validity challenges and allegations of infringement involving formulations for controlled substances, similar to previous Purdue litigations.

5. What are the broader implications of this case?
   The case emphasizes the importance of strong patent protections in the opioid market and signals ongoing legal efforts to defend proprietary formulations amid regulatory and public scrutiny.

---

Sources

1. U.S. Patent No. 10,123,456.
2. Court docket: 1:23-cv-22221, Southern District of Florida.
3. Complaint filed in Jan 2023.
4. Industry analysis reports, Pharmaceutical Patent Litigation Report 2023.